Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial.
bleeding
blood loss
complications
cost effectiveness
total hip arthroplasty
total knee arthroplasty
tranexamic acid
transfusion
Journal
British journal of anaesthesia
ISSN: 1471-6771
Titre abrégé: Br J Anaesth
Pays: England
ID NLM: 0372541
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
11
10
2022
revised:
09
11
2022
accepted:
10
11
2022
pmc-release:
01
02
2024
pubmed:
17
12
2022
medline:
24
1
2023
entrez:
16
12
2022
Statut:
ppublish
Résumé
Tranexamic acid (TXA) reduces rates of blood transfusion for total hip arthroplasty (THA) and total knee arthroplasty (TKA). Although the use of oral TXA rather than intravenous (i.v.) TXA might improve safety and reduce cost, it is not clear whether oral administration is as effective. This noninferiority trial randomly assigned consecutive patients undergoing primary THA or TKA under neuraxial anaesthesia to either one preoperative dose of oral TXA or one preoperative dose of i.v. TXA. The primary outcome was calculated blood loss on postoperative day 1. Secondary outcomes were transfusions and complications within 30 days of surgery. Four hundred participants were randomised (200 THA and 200 TKA). The final analysis included 196 THA patients (98 oral, 98 i.v.) and 191 TKA patients (93 oral, 98 i.v.). Oral TXA was non-inferior to i.v. TXA in terms of calculated blood loss for both THA (effect size=-18.2 ml; 95% confidence interval [CI], -113 to 76.3; P<0.001) and TKA (effect size=-79.7 ml; 95% CI, -178.9 to 19.6; P<0.001). One patient in the i.v. TXA group received a postoperative transfusion. Complication rates were similar between the two groups (5/191 [2.6%] oral vs 5/196 [2.6%] i.v.; P=1.00). Oral TXA can be administered in the preoperative setting before THA or TKA and performs similarly to i.v. TXA with respect to blood loss and transfusion rates. Switching from i.v. to oral TXA in this setting has the potential to improve patient safety and decrease costs.
Sections du résumé
BACKGROUND
Tranexamic acid (TXA) reduces rates of blood transfusion for total hip arthroplasty (THA) and total knee arthroplasty (TKA). Although the use of oral TXA rather than intravenous (i.v.) TXA might improve safety and reduce cost, it is not clear whether oral administration is as effective.
METHODS
This noninferiority trial randomly assigned consecutive patients undergoing primary THA or TKA under neuraxial anaesthesia to either one preoperative dose of oral TXA or one preoperative dose of i.v. TXA. The primary outcome was calculated blood loss on postoperative day 1. Secondary outcomes were transfusions and complications within 30 days of surgery.
RESULTS
Four hundred participants were randomised (200 THA and 200 TKA). The final analysis included 196 THA patients (98 oral, 98 i.v.) and 191 TKA patients (93 oral, 98 i.v.). Oral TXA was non-inferior to i.v. TXA in terms of calculated blood loss for both THA (effect size=-18.2 ml; 95% confidence interval [CI], -113 to 76.3; P<0.001) and TKA (effect size=-79.7 ml; 95% CI, -178.9 to 19.6; P<0.001). One patient in the i.v. TXA group received a postoperative transfusion. Complication rates were similar between the two groups (5/191 [2.6%] oral vs 5/196 [2.6%] i.v.; P=1.00).
CONCLUSIONS
Oral TXA can be administered in the preoperative setting before THA or TKA and performs similarly to i.v. TXA with respect to blood loss and transfusion rates. Switching from i.v. to oral TXA in this setting has the potential to improve patient safety and decrease costs.
Identifiants
pubmed: 36526484
pii: S0007-0912(22)00635-3
doi: 10.1016/j.bja.2022.11.003
pmc: PMC9900725
pii:
doi:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Antifibrinolytic Agents
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
234-241Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
Am J Surg. 1996 Mar;171(3):324-30
pubmed: 8615466
Eur J Clin Pharmacol. 1981;20(1):65-72
pubmed: 7308275
J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460
pubmed: 30180053
Osteoarthritis Cartilage. 2015 Apr;23(4):594-600
pubmed: 25579802
J Arthroplasty. 2013 Sep;28(8 Suppl):137-9
pubmed: 23886409
J Arthroplasty. 2016 Sep;31(9 Suppl):26-30
pubmed: 27113948
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Bone Joint Surg Am. 2007 Apr;89(4):780-5
pubmed: 17403800
J Arthroplasty. 2017 Jan;32(1):320-325
pubmed: 27682006
Anesthesiology. 1983 Mar;58(3):277-80
pubmed: 6829965
J Orthop Trauma. 2022 Jun 1;36(6):e215-e226
pubmed: 34799543
Medicine (Baltimore). 2020 Oct 30;99(44):e22999
pubmed: 33126380
Hip Int. 2018 Jul;28(4):382-390
pubmed: 29218687
Anaesthesia. 2019 Jul;74(7):904-914
pubmed: 30985928
Acta Orthop. 2008 Apr;79(2):168-73
pubmed: 18484241
J Arthroplasty. 2004 Apr;19(3):281-7
pubmed: 15067638
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Bone Joint Surg Am. 2019 Dec 4;101(23):2120-2128
pubmed: 31800425